BizClik Launches January 2026 Sustainability Portfolio With Insights From Novartis and Amazon GlobeNewswire January 08, 2026 The January 2026 edition of BizClik's Sustainability portfolio is now live, featuring fresh insights from Sustainability Magazine. This month's issues spotlight global leaders, breakthrough technologies, and critical sustainability strategies. London – 8 January 2026- BizClik, a global B2B media […]

(NYSE:TFX), Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Revenue Results WAYNE, Pa., Jan. 08, 2026 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) today announced that Stuart Randle, a member of the Company's Board

(TSX-V:NGEN),(OTC US:NGENF),(OTCQB:NGENF),(NASDAQ:NGEN), VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the Company's common shares have been approved for listing on Nasdaq. NervGen's

(NasdaqGM:XMAG), MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) — Defiance ETFs today announced that the Defiance Large Cap Ex-Magnificent Seven ETF (XMAG) has surpassed $100 million in assets under management, marking a significant milestone since the fund's launch in October 2024. XMAG is designed to provide investors with exposure to the S&P 500 while excluding the

Company Positioned for Strategic Transaction MALVERN, PA / ACCESS Newswire / January 8, 2026 / Toetal Solution, Inc., a Runway Healthcare company, announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Ziptoe™ Hammertoe System, an implant designed for proximal interphalangeal joint (PIPJ) arthrodesis in hammertoe correction procedures. The Ziptoe

Teleflex Announces Leadership Transition GlobeNewswire January 08, 2026 Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Revenue Results WAYNE, Pa., Jan. 08, 2026 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) today announced that Stuart

NervGen Pharma Begins Trading on Nasdaq Today GlobeNewswire January 08, 2026 VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the Company's common

Diagonal Therapeutics Announces Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Disease-Modifying, Clustering Antibody Pipeline GlobeNewswire January 08, 2026 Financing co-led by Sanofi Ventures and Janus Henderson Investors, with participation from new investors Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management L.P., Woodline Partners LP and all existing investors Proceeds

(Milan:RACE),(NYSE:RACE), Maranello (Italy), January 8, 2026 – Ferrari N.V. (“Ferrari“) (NYSE/EXM: RACE) announced today that its financial results for the full year and fourth quarter of 2025 will be released on Tuesday, February 10, 2026. A live audio webcast and conference call of the 2025 full year and fourth quarter results will begin at 2:00

FERRARI TO ANNOUNCE 2025 FULL YEAR AND FOURTH QUARTER FINANCIAL RESULTS ON FEBRUARY 10 GlobeNewswire January 08, 2026 Maranello (Italy), January 8, 2026 – Ferrari N.V. (“Ferrari“) (NYSE/EXM: RACE) announced today that its financial results for the full year and fourth quarter of 2025 will be released on Tuesday, February 10, 2026. A live audio